Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has been awarded a standing offer by t

WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today a

GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awaren

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Emergen

[url="]Schall, Brown and Schwartz[/url] LLP (“SBS”), a national shareholder rights litigation fi

LOS ANGELES--(BUSINESS WIRE)---- $EBS--EBS Investors Have Opportunity to Join Emergent BioSolutions

Emergent BioSolutions reported approximately $97 million in adjusted EBITDA for the quarter. The sam

Emergent BioSolutions shares sold off after the Company posted roughly $234 million in quarterly rev

Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Company disclosed a $191.3 mill

NEW YORK--(BUSINESS WIRE)--Emergent BioSolutions (NYSE: EBS) shareholders took losses after the Comp

Emergent BioSolutions cut its FY2026 adjusted EBITDA outlook to $130-$150 million from $155-$175 mil

Emergent BioSolutions cut FY2026 revenue guidance to $645-$675 million after reaffirming a $720-$760

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) wit

Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its p

Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript

Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday'

Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday&

Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 mill

Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $720.000 million-$760.000 million

GAITHERSBURG, Md. , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS), a global bi

Second Quarter 2026 Total Revenues of $234. 3 million, an improvement of 66% versus prior year Secon

Emergent BioSolutions (NYSE:EBS) today announced it has been awarded a contract modification valued

https://www.fda.gov/news-events/press-announcements/fda-broadens-access-over-counter-naloxone-nasal-

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has been awarded a contract modification va

https://www.cdc.gov/ebola/situation-summary/index.html

Emergent BioSolutions (NYSE:EBS), a global biodefense company, today announced that the Saudi Food a

Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 mill

Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million

Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analy

Emergent BioSolutions Inc. (NYSE:EBS) today announced that Singapore's Health Sciences Authority

The executed agreement is valued at approximately $50 million, of which $36 million is contingent on

Emergent BioSolutions Inc. (NYSE:EBS) today announced it has entered into an agreement with Substiph

Emergent BioSolutions (NYSE:EBS) announced that it has partnered with the B.C. Provincial Health Ser

Emergent BioSolutions Inc. (NYSE: EBS) today announced it has secured a contract award valued at app

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) wit

U.S. stocks down mid-trading, Nasdaq falls 1%. Dow down 1.40%, S&P 500 falls 0.74%. Dell shares

US stocks traded lower, Dow down 600 points. Nasdaq and S&P also fell. Consumer staples up, tech

Emergent BioSolutions (NYSE:EBS) sees FY2026 sales of $720.000 million-$760.000 million vs $1.155 bi